NCT03350633View on ClinicalTrials.gov

Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

September 1, 2019

Study Completion Date

September 1, 2019

Conditions
Neuromyelitis Optica Spectrum DisordersNeuromyelitis Optica
Interventions
DRUG

Tocilizumab Injection

Tocilizumab Injection will be intravenously administered with a dose of 8 mg/kg every 4 weeks.

DRUG

Azathioprine

Azathioprine will be orally given at a dose of 2-3 mg/kg/d

Trial Locations (1)

300052

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University General Hospital

OTHER

NCT03350633 - Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders | Biotech Hunter | Biotech Hunter